메뉴 건너뛰기
Annals of Indian Academy of Neurology
Volumn 13, Issue 4, 2010, Pages 313-
Beta-interferons in multiple sclerosis
Author keywords

[No Author keywords available]
Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; GAMMA INTERFERON; GLATIRAMER; INTERLEUKIN 2; MITOXANTRONE; NATALIZUMAB; TUMOR NECROSIS FACTOR ALPHA;
EID: 78650934151     PISSN: 09722327     EISSN: 19983549     Source Type: Journal    
DOI: 10.4103/0972-2327.74189     Document Type: Letter
Times cited : (2)
References (7)
  • 1
    • 77954225813 scopus 로고    scopus 로고
    • Beta-interferons in multiple sclerosis: A single center experience in India
    • Gupta S, Varadarajulu R, Ganjoo RK. Beta-interferons in multiple sclerosis: A single center experience in India. Ann Indian Acad Neurol 2010;13:132-5.
    • (2010) Ann Indian Acad Neurol , vol.13 , pp. 132-5
    • Gupta, S.1    Varadarajulu, R.2    Ganjoo, R.K.3
  • 2
    • 70349411720 scopus 로고    scopus 로고
    • Efficacy and safety of Mitoxantrone, as an initial therapy, in multiple sclerosis: Experience in an Indian tertiary care setting
    • Singhal BS, Geeta S, Hundalani SG, Menon S. Efficacy and safety of Mitoxantrone, as an initial therapy, in multiple sclerosis: Experience in an Indian tertiary care setting. Neurol India 2009;57:418-23.
    • (2009) Neurol India , vol.57 , pp. 418-23
    • Singhal, B.S.1    Geeta, S.2    Hundalani, S.G.3    Menon, S.4
  • 3
    • 10944231932 scopus 로고    scopus 로고
    • Mechanism of action of mitoxantrone
    • Fox EJ. Mechanism of action of mitoxantrone. Neurology 2004;63:S15-8.
    • (2004) Neurology , vol.63
    • Fox, E.J.1
  • 4
    • 46849091551 scopus 로고    scopus 로고
    • Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis
    • Vollmer T, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, et al. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler 2008;14:663-70.
    • (2008) Mult Scler , vol.14 , pp. 663-70
    • Vollmer, T.1    Panitch, H.2    Bar-Or, A.3    Dunn, J.4    Freedman, M.S.5    Gazda, S.K.6
  • 5
    • 70349414132 scopus 로고    scopus 로고
    • Alemtuzumab Induces a Sustained Reduction in Disability in Patients with Relapsing Remitting Multiple Sclerosis. American Academy of Neurology
    • CAMMS223 Study Group
    • Coles AJ. CAMMS223 Study Group. Alemtuzumab Induces a Sustained Reduction in Disability in Patients with Relapsing Remitting Multiple Sclerosis. American Academy of Neurology. 61 st Annual Meeting, 2009. p. 145
    • (2009) 61 St Annual Meeting , pp. 145
    • Coles, A.J.1
  • 6
    • 70349423267 scopus 로고    scopus 로고
    • Natalizumab Reduces Clinical and MRI Disease Activity in Second Line Treatment of Relapsing Remitting Multiple Sclerosis: Results of a Multicenter Study. American Academy of Neurology
    • Putzki N, Yaldizli O, Murer M, Kuckert S, Cursiefen S, Tettenborn B, et al. Natalizumab Reduces Clinical and MRI Disease Activity in Second Line Treatment of Relapsing Remitting Multiple Sclerosis: Results of a Multicenter Study. American Academy of Neurology. 61 st Annual Meeting, 2009. p. 5-128
    • (2009) 61 St Annual Meeting , pp. 5-128
    • Putzki, N.1    Yaldizli, O.2    Murer, M.3    Kuckert, S.4    Cursiefen, S.5    Tettenborn, B.6
  • 7
    • 60049083956 scopus 로고    scopus 로고
    • Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: A phase I/II study
    • Burt RK, Loh Y, Cohen B, Stefoski D, Balabanov R, Katsamakis G, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: A phase I/II study. Lancet Neurol 2009;8:244-53
    • (2009) Lancet Neurol , vol.8 , pp. 244-53
    • Burt, R.K.1    Loh, Y.2    Cohen, B.3    Stefoski, D.4    Balabanov, R.5    Katsamakis, G.6

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.